Nemonapride is a potent dopamine D2receptor antagonist antipsychotic reported to
have superior efficacy against hallucinations and delusions and also to be effective in
the treatment of negative symptoms. The compound is a benzamide diastereomer and,
although more potent than haloperidol, side effects are reported to be few primarily
akinesia and some muscle rigidity with extrapyramidal symptoms being rare.
Nemonapride is an antipsychotic that readily passes through the blood brain barrier and exhibits potent neuroleptic effects in animals. It binds dopamine 2 (D2)-like receptors preferentially over D1-like receptors (Kis = 0.06, 0.3, and 0.15 nM for D2, D3, and D4, respectively). Nemonapride also binds sigma 1 (σ1) and σ2 receptors (Kis = 8.4 and 9.6 nM, respectively) and activates the serotonin 1A receptor (5-HT1A; IC50 = 34 nM).
Colourless Crystalline Solid
Nemonapride is a selective dopamine D2 receptor antagonist. Nemonapride is used as an antipsychotic.
A selective dopamine D2 receptor antagonist. Used as an antipsychotic
ChEBI: (2R,3R)-nemonapride is an optically active form of nemonapride having (2R,3R)-configuration. It is a conjugate base of a (2R,3R)-nemonapride(1+). It is an enantiomer of a (2S,3S)-nemonapride.
Highly potent dopamine D 2 -like receptor antagonist; selective over D 1 -like receptors (K i values are 0.1 and 740 nM for D 2 -like and D 1 -like receptors respectively). Also potent 5-HT 1A receptor agonist (IC 50 = 34 nM) and has affinity for sigma receptors.
